GNW-Adhoc: New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202

^Allschwil, Switzerland - June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia's investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, will be presented as an oral presentation by Prof. M...

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,Milan ,Lombardia ,Italy ,Japan ,United States ,Australia ,Swiss ,American ,Andrewc Weiss ,Arthurc Corcoran ,Markus Schlaich ,Hypertension Council ,Idorsia Pharmaceuticals Ltd ,Swiss Exchange ,American Heart Association ,European Society ,European Society Of Hypertension ,Idorsia Ltd ,European Society Of Cardiology ,International Society Of Hypertension ,Head Of Investor Relations Corporate Communications ,European Meeting ,Uncontrolled Hypertension ,Breaking Science ,Management Board ,High Blood ,Editorial Board ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,